Kang Jin Jeong - Concepedia

Author

Kang Jin Jeong

The University of Texas MD Anderson Cancer Center ORCID

Also Known As

Jeong K., Jeong, Kang, K Jeong, KANG JIN JEONG, Kang Jin Jeong, Kang J. Jeong, Kang Jeong, Kang Jin Jeong, Kang Jin Jeong, N Murali

137

Publications

Citations

H-Index

Concepts

All Affiliations

The University of Texas MD Anderson Cancer Center Konyang University Baylor College of Medicine Harvard University Oregon Health & Science University

About

Kang Jin Jeong is an author at The University of Texas MD Anderson Cancer Center specializing in medicine, tumor biology, and cell biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	17	18	2.9K
2	Engineering	3	3	915
3	Health Sciences	3	3	257
4	Natural Sciences	2	2	74
5	Biochemistry	1	1	14

Kang Jin Jeong

Publications

7.3K

Citations

H-Index

Page 1

	Year	Citations
Comprehensive Characterization of Cancer Driver Genes and Mutations Matthew H. Bailey, Collin Tokheim, Eduard Porta‐Pardo, Cell	2018	2.4K
A Pan-Cancer Proteogenomic Atlas of PI3K/AKT/mTOR Pathway Alterations Yiqun Zhang, Patrick Kwok‐Shing Ng, Melanie H. Kucherlapati, Cancer Cell Tumor BiologyCancer GenomicsPi3k/akt/mtor Pathway AlterationsTumor SuppressorSystems Biology	2017	646
The Genomic Landscape and Clinical Relevance of A-to-I RNA Editing in Human Cancers Leng Han, Lixia Diao, Shuangxing Yu, Cancer Cell A-to-i Rna EditingTumor BiologyEngineeringGenomic LandscapeMedicine	2015	563
Comprehensive Molecular Characterization of the Hippo Signaling Pathway in Cancer Yumeng Wang, Xiaoyan Xu, Dejan Maglic, Cell Reports	2018	493
Systematic Functional Annotation of Somatic Mutations in Cancer Patrick Kwok‐Shing Ng, Jun Li, Kang Jin Jeong, Cancer Cell Somatic VariantCancer GenomicsSystematic Functional AnnotationCancer GeneticsSystems Biology	2018	347
BRD4 Inhibition Is Synthetic Lethal with PARP Inhibitors through the Induction of Homologous Recombination Deficiency Chaoyang Sun, Jun‐Jie Yin, Yong Fang, Cancer Cell Homologous Recombination DeficiencyEngineeringMolecular BiologySynthetic BiologyRecombination Dynamic	2018	295
A-to-I RNA Editing Contributes to Proteomic Diversity in Cancer Xinxin Peng, Xiaoyan Xu, Yumeng Wang, Cancer Cell Proteomic DiversityRna BiologyGene ExpressionMedicineCell Biology	2018	242
Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in <i>RAS</i> mutant cancers Chaoyang Sun, Yong Fang, Jun‐Jie Yin, Science Translational Medicine	2017	231
Sequential Therapy with PARP and WEE1 Inhibitors Minimizes Toxicity while Maintaining Efficacy Yong Fang, Daniel J. McGrail, Chaoyang Sun, Cancer Cell Clinical TherapeuticMedicinePharmacotherapyPharmacologyNovel Therapy	2019	231
Systematic characterization of A-to-I RNA editing hotspots in microRNAs across human cancers Yumeng Wang, Xiaoyan Xu, Shuangxing Yu, Genome Research	2017	176

Page 1